1887

Abstract

The middle-sized (M) surface proteins of hepatitis B virus (HBV) and other orthohepadnaviruses contain a conserved -glycan in their pre-S2 domain, which is essential for the secretion of viral particles. Recently, we also found -glycans in the pre-S2 domain of M protein from woodchuck hepatitis virus (WHV) and HBV genotype D. Since the -glycosylation motif is not conserved in all genotypes of HBV, the glycosylation patterns of HBV genotypes A and C were analysed. Pre-S2 (glyco)peptides were released from HBV-carrier-derived HBV subviral particles by tryptic digestion, purified by reversed-phase HPLC and identified by amino acid and amino-terminal sequence analysis as well as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Pre-S2 -glycans were characterized by anion-exchange chromatography, methylation analysis and on-target sequential exoglycosidase digestions in combination with MALDI-TOF-MS, demonstrating the presence of partially sialylated diantennary complex-type oligosaccharides in all genotypes examined. Pre-S2 -glycans were characterized by on-target sequential exoglycosidase digestions in combination with MALDI-TOF-MS. The pre-S2 domain of M protein and, to a minor extent, of L (large) protein from HBV genotype C and D was partially -glycosylated by Neu5Ac(2–3)Gal(1–3)GalNAc- or Gal(1–3)GalNAc-units at Thr-37 within a conserved sequence context. Genotype A, containing no Thr at position 37 or 38, was not -glycosylated. Analytical data further revealed that M protein is mostly amino-terminally acetylated in all examined genotypes and that the terminal methionine is partially oxidized. The findings may be relevant for the secretion and the immunogenicity of HBV.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.79932-0
2004-07-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/7/vir852045.html?itemId=/content/journal/jgv/10.1099/vir.0.79932-0&mimeType=html&fmt=ahah

References

  1. Bartholomeusz A., Schaefer S. 2004; Hepatitis B virus genotypes – comparison of genotyping methods. Rev Med Virol 14:3–16 [CrossRef]
    [Google Scholar]
  2. Block T. M., Lu X., Platt F. M., Foster G. R., Gerlich W. H., Blumberg B. S., Dwek R. A. 1994; Secretion of human hepatitis B virus is inhibited by the imino sugar N -butyldeoxynojirimycin. Proc Natl Acad Sci U S A 91:2235–2239 [CrossRef]
    [Google Scholar]
  3. Block T. M., Lu X., Mehta A. S. 7 other authors 1998; Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 4:610–614 [CrossRef]
    [Google Scholar]
  4. Bruss V., Ganem D. 1991; The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A 88:1059–1063 [CrossRef]
    [Google Scholar]
  5. Bruss V., Lu X., Thomssen R., Gerlich W. H. 1994; Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J 13:2273–2279
    [Google Scholar]
  6. Carman W. F. 1997; The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4:11–20 [CrossRef]
    [Google Scholar]
  7. DeWilde M., Rutgers T., Cabezon T. 13 other authors 1991; PreS-containing HBsAg particles from Saccaromyces cerevisae : production, antigenicity. In Viral Hepatitis and Liver Disease pp  732–736 Edited by Hollinger F. B., Lemon S. M., Margolis H. S. Baltimore: Williams & Wilkins;
    [Google Scholar]
  8. Eble B. E., Lingappa V. R., Ganem D. 1990; The N-terminal (pre-S2) domain of a hepatitis B virus surface glycoprotein is translocated across membranes by downstream signal sequences. J Virol 64:1414–1419
    [Google Scholar]
  9. Emini E. A., Larson V., Eichberg J. 7 other authors 1989; Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein. J Med Virol 28:7–12 [CrossRef]
    [Google Scholar]
  10. Ganem D., Schneider R. J. 2001; Hepadnaviridae: the viruses and their replication. In Fields Virology , 4th edn. pp  2923–2969 Edited by Knipe D. M., Howley P. M. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
  11. Gerlich W. H., Wend U., Glebe D. 2003; Quantitative assay of hepatitis B surface antigen in serum or plasma using Laurell electrophoresis. In Hepatitis B Virus Protocols pp  57–63 Edited by Lau J., Hamatake R. K. Totowa, NJ: Humana Press;
    [Google Scholar]
  12. Gillece-Castro B. L., Fisher S. J., Tarentino A. L., Peterson D. L., Burlingame A. L. 1987; Structure of the oligosaccharide portion of human hepatitis B surface antigen. Arch Biochem Biophys 256:194–201 [CrossRef]
    [Google Scholar]
  13. Glebe D., Gerlich W. H. 2003; Study of the endocytosis and intracellular localization of subviral particles of HBV in primary hepatocytes. In Hepatitis B Virus Protocols pp  143–151 Edited by Lau J., Hamatake R. K. Totowa, NJ: Humana Press;
    [Google Scholar]
  14. Glebe D., Aliakbari M., Krass P., Knoop E. V., Valerius K. P., Gerlich W. H. 2003; Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 77:9511–9521 [CrossRef]
    [Google Scholar]
  15. Gripon P., Rumin S., Urban S. 7 other authors 2002; Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99:15655–15660 [CrossRef]
    [Google Scholar]
  16. Hansen J. E., Lund O., Tolstrup N., Gooley A. A., Williams K. L., Brunak S. 1998; NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj J 15:115–130 [CrossRef]
    [Google Scholar]
  17. Heermann K. H., Goldmann U., Schwartz W., Seyffarth T., Baumgarten H., Gerlich W. H. 1984; Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 52:396–402
    [Google Scholar]
  18. Hollinger F. B., Liang T. J. 2001; Hepatitis B virus. In Fields Virology , 4th edn. pp  2971–3036 Edited by Knipe D. M., Howley P. M. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
  19. Itoh Y., Takai E., Ohnuma H. 7 other authors 1986; A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci U S A 83:9174–9178 [CrossRef]
    [Google Scholar]
  20. Jungers P., Chauveau P., Courouce A. M., Devillier P., Excler J. L., Bailleux F., Saliou P. 1994; Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. J Infect Dis 169:399–402 [CrossRef]
    [Google Scholar]
  21. Kann M., Gerlich W. H. 1998; Hepatitis B. In Topley & Wilson's Microbiology and Microbial Infections . , 9th edn. pp  745–774 Edited by Collier L., Balows A., Sussman M. London: Arnold;
  22. Lanford R. E., Chavez D., Brasky K. M., Burns R. B. III, Rico-Hesse R. 1998; Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A 95:5757–5761 [CrossRef]
    [Google Scholar]
  23. Leroux-Roels G., Desombere I., Cobbaut L., Petit M. A., Desmons P., Hauser P., Delem A., De Grave D., Safary A. 1997; Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine 15:1732–1736 [CrossRef]
    [Google Scholar]
  24. Lu X., Mehta A., Dwek R., Butters T., Block T. 1995; Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virology 213:660–665 [CrossRef]
    [Google Scholar]
  25. Mehta A., Lu X., Block T. M., Blumberg B. S., Dwek R. A. 1997; Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A 94:1822–1827 [CrossRef]
    [Google Scholar]
  26. Michel M. L., Pol S., Brechot C., Tiollais P. 2001; Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 19:2395–2399 [CrossRef]
    [Google Scholar]
  27. Milich D. R., Hughes J. L., McLachlan A., Langley K. E., Thornton G. B., Jones J. E. 1990; Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. I. T cell fine specificity. J Immunol 144:3535–3543
    [Google Scholar]
  28. Neurath A. R., Kent S. B., Parker K., Prince A. M., Strick N., Brotman B., Sproul P. 1986a; Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 4:35–37 [CrossRef]
    [Google Scholar]
  29. Neurath A. R., Kent S. B., Strick N., Parker K. 1986b; Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46:429–436 [CrossRef]
    [Google Scholar]
  30. Pfeiffer G., Linder D., Strube K. H., Geyer R. 1993; Glycosylation of the thrombin-like serine protease ancrod from Agkistrodon rhodostoma venom. Oligosaccharide substitution pattern at each N-glycosylation site. Glycoconj J 10:240–246
    [Google Scholar]
  31. Pontisso P., Ruvoletto M. G., Gerlich W. H., Heermann K. H., Bardini R., Alberti A. 1989; Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology 173:522–530 [CrossRef]
    [Google Scholar]
  32. Schaefer S., Glebe D., Wend U. C., Oyunbileg J., Gerlich W. H. 2003; Universal primers for real-time amplification of DNA from all known Orthohepadnavirus species. J Clin Virol 27:30–37 [CrossRef]
    [Google Scholar]
  33. Schmitt S., Glebe D., Alving K. 7 other authors 1999; Analysis of the pre-S2 N - and O -linked glycans of the M surface protein from human hepatitis B virus. J Biol Chem 274:11945–11957 [CrossRef]
    [Google Scholar]
  34. Shapira M. Y., Zeira E., Adler R., Shouval D. 2001; Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 34:123–127 [CrossRef]
    [Google Scholar]
  35. Sheu S. Y., Lo S. J. 1994; Biogenesis of the hepatitis B viral middle (M) surface protein in a human hepatoma cell line: demonstration of an alternative secretion pathway. J Gen Virol 75:3031–3039 [CrossRef]
    [Google Scholar]
  36. Sobotta D., Sominskaya I., Jansons J., Meisel H., Schmitt S., Heermann K. H., Kaluza G., Pumpens P., Gerlich W. H. 2000; Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol 81:369–378
    [Google Scholar]
  37. Stibbe W., Gerlich W. H. 1983; Characterization of pre-s-gene products in hepatitis B surface antigen. Dev Biol Stand 54:33–43
    [Google Scholar]
  38. Tai P. C., Suk F. M., Gerlich W. H., Neurath A. R., Shih C. 2002; Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants. Virology 292:44–58 [CrossRef]
    [Google Scholar]
  39. Tolle T. K., Glebe D., Linder M., Linder D., Schmitt S., Geyer R., Gerlich W. H. 1998; Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J Virol 72:9978–9985
    [Google Scholar]
  40. Werr M., Prange R. 1998; Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J Virol 72:778–782
    [Google Scholar]
  41. Young M. D., Schneider D. L., Zuckerman A. J., Du W., Dickson B., Maddrey W. C. US Hepacare Group 2001; Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology 34:372–376 [CrossRef]
    [Google Scholar]
  42. Zuckerman J. N., Sabin C., Craig F. M., Williams A., Zuckerman A. J. 1997; Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 314:329–333 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.79932-0
Loading
/content/journal/jgv/10.1099/vir.0.79932-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error